Management of Moderate to Severe COPD

Core Pharmacologic Therapy

The American Thoracic Society recommends combination long-acting bronchodilator therapy (LABA/LAMA) as the foundation of treatment for moderate to severe COPD, with the addition of inhaled corticosteroids if the patient has frequent exacerbations or elevated eosinophils 1, 2
Combination LABA/LAMA therapy provides superior symptom control and lung function improvement compared to monotherapy, reducing dynamic hyperinflation, improving exercise tolerance, and decreasing exacerbation frequency 1
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests that patients with frequent exacerbations (≥2 per year or ≥1 requiring hospitalization) or elevated peripheral eosinophil counts should be considered for triple therapy with LABA/LAMA and inhaled corticosteroids 1, 3, 4

The American College of Chest Physicians recommends smoking cessation as the only intervention proven to modify disease progression, and must be addressed aggressively, with first-line options including varenicline, bupropion, and nicotine replacement therapy 1, 2
These medications must be combined with behavioral counseling for maximum effectiveness, as pharmacotherapy alone is insufficient 1, 2

The Centers for Disease Control and Prevention (CDC) recommends annual influenza vaccination to reduce serious illness, mortality, exacerbations, and cardiovascular events in patients with COPD 1, 2
The CDC also recommends pneumococcal vaccination with PCV13 (Prevnar 13) and PPSV23 (Pneumovax 23) for all patients ≥65 years, and consideration of pneumococcal vaccination for patients <65 years with moderate to severe COPD based on individual risk 1, 2

The European Respiratory Society suggests considering the addition of theophylline (target serum level 5-15 μg/mL) if symptoms persist despite LABA/LAMA therapy, with close monitoring for side effects including cardiac arrhythmias, GI upset, and drug interactions 3, 4, 5
The American Thoracic Society recommends long-term oxygen therapy (LTOT) for patients with severe resting hypoxemia (SpO2 <89%), as it is the only treatment besides smoking cessation that improves survival in severe COPD 1, 2

The American Thoracic Society recommends primary pharmacologic treatments for COPD management, including bronchodilators and inhaled corticosteroids in specific cases 6
For mild COPD with no symptoms, the European Respiratory Society recommends no drug treatment 7, 6
For symptomatic mild COPD, the European Respiratory Society recommends short-acting beta-agonists or anticholinergics as needed 7, 6
For moderate COPD, the European Respiratory Society recommends long-acting bronchodilator monotherapy as the standard of care 7, 8, 6
For severe COPD, the European Respiratory Society recommends combination therapy with long-acting beta-agonists and long-acting muscarinic antagonists 8, 6

The European Respiratory Society recommends specific additional treatments for COPD, including theophylline, roflumilast, macrolides, and N-acetylcysteine/oral carbocisteine 9, 10
The American Academy of Family Physicians indicates that montelukast is primarily used for asthma management, with established efficacy as an alternative therapy for mild persistent asthma 11, 12

The European Respiratory Society notes that potential neuropsychiatric adverse events have been reported with montelukast use, which should be considered in risk-benefit assessments 13

The American College of Chest Physicians recommends that clinicians follow evidence-based approaches using short-acting bronchodilators, long-acting bronchodilators, and inhaled corticosteroids for COPD management 7, 8, 6
The European Respiratory Society advises that montelukast should not be routinely prescribed for COPD patients due to the lack of supporting evidence in guidelines and limited research data 6

Adding another benzodiazepine to a person already receiving lorazepam can cause excessive sedation and markedly increase the risk of respiratory depression in COPD, making this combination especially hazardous. [European Respiratory Society COPD guidelines, 1995] 14
The European Respiratory Society COPD guidelines note that anxiolytic drugs have inconsistent effects on dyspnea and that sedatives may exacerbate respiratory depression. [European Respiratory Society COPD guidelines, 1995] 15

All medications that depress respiration should be avoided in individuals with COPD because they can precipitate respiratory failure. [European Respiratory Society COPD guidelines, 1995] 14
Opioids such as morphine are identified in the European Respiratory Society COPD guidelines as having the highest risk of respiratory depression and should be limited to end‑stage disease. [European Respiratory Society COPD guidelines, 1995] 15
Co‑administration of lorazepam with additional sedating agents requires careful monitoring for cumulative respiratory‑depressant effects. [European Respiratory Society COPD guidelines, 1995] 14

Theophylline, occasionally cited for tremor, is contraindicated in COPD because of its narrow therapeutic window and significant drug‑interaction potential. [European Respiratory Society COPD guidelines, 1995] 16
Use of excessive benzodiazepines beyond the existing lorazepam regimen is discouraged due to the heightened risk of respiratory depression in COPD. [European Respiratory Society COPD guidelines, 1995] 15